Market Definition
Hyperphosphatemia is the high levels of inorganic phosphate in the blood. High phosphate levels in the blood can be reduced by the use of phosphate binders and dietary constraints of phosphates.
Market Dynamics
The rising prevalence and incidence of chronic kidney diseases is a key driving factor of the market. According to the Centers for Disease Control and Prevention, the global prevalence of chronic kidney diseases is 13.4%. According to the Centers for Disease Control and Prevention, around 15% of US adults, which is 37 million people had chronic kidney diseases in 2020. In Canada, around 4 million people have chronic kidney diseases. According to the NHS England, more than 1.8 million people in England were diagnosed with chronic kidney disease (CKD) in 2019. Around 19·5 million have been diagnosed with chronic kidney disease in China. The prevalence of chronic kidney disease was 10.8% in 2019. According to the Australian Institute of Health and Welfare, around 1.7 million (10%) Australian adults with age 18 years and over had biomedical signs of chronic kidney disease (CKD). However, the side effects of hyperphosphatemia drugs might hamper the market growth. Some of the common side effects of hyperphosphatemia drugs include vomiting, nausea, diarrhea, indigestion, abdominal pain, gas, and constipation. Moreover, the high potential of hyperphosphatemia drugs in untapped economies, including India, China, South Africa, and Brazil, would provide lucrative opportunities for the market in coming years.
Market Segmentation
The global hyperphosphatemia drugs market is mainly classified based on type and dosage form. Type is further segmented into Calcium-based Phosphate Binders, Magnesium-based Phosphate Binders, Aluminum-based Phosphate Binders, Iron-based Phosphate Binders, and Other Phosphate Binders. By dosage form, the market is divided into Capsules, Tablets, and Syrups.
Based on dosage form, Tablets has shown significant growth in 2020, owing to the increasing regulatory approval of hyperphosphatemia tablets, the partnership between companies to expand its product portfolio and presence in the global market, and commercialization of new hyperphosphatemia tablets. For instance, Kissei Pharmaceutical Co., Ltd. has introduced P-TOL Granules 250 mg and P-TOL Granules 500 mg in Japan for the treatment of hyperphosphatemia. P-TOL Granules 250 mg and P-TOL Granules 500 mg are new dosage forms of P-TOL Chewable tablets. P-TOL decreases serum phosphate concentration through the binding of oxyhydroxide iron with phosphoric acid in the gastrointestinal tract and reduces in vivo phosphate absorption.
Regional Analysis
Based on geography, the global hyperphosphatemia drugs market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided into the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.
North America was dominating the global hyperphosphatemia drugs market in 2020 due to the prevalence and incidence of chronic kidney diseases and the increasing prevalence of diabetes & osteoporosis across the region. In North America, the prevalence of chronic kidney diseases is very high in the elderly population, with more than 35% of patients over age 70 years suffering from stage 3 chronic kidney disease. Moreover, increasing regulatory approval for New Drug Application (NDA) for hyperphosphatemia drugs in the United States is boosting the market growth. For instance, Ardelyx, Inc., a biopharmaceutical company focused on developing first-in-class medicines for the treatment of people with kidney and cardiovascular diseases, has received U.S. Food and Drug Administration (FDA) acceptance for its New Drug Application (NDA) of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
Competitive landscape
Key players operating in the hyperphosphatemia drugs industry include Keryx Biopharmaceuticals, Sun Pharmaceutical, Ultragenyx, Pfizer Inc, Vifor Pharma, Sanofi, Takeda Pharmaceutical, Fresenius Medical Care, Emcure Pharma, and Ardelyx, Inc.
The collaboration between companies to develop and expand its market presence for hyperphosphatemia drugs, increasing regulatory approval for hyperphosphatemia drugs, strategic acquisition to extend product portfolio and geographic presence and commercialization of new generic version of hyperphosphatemia drugs are some of the strategies adopted by the major companies. For instance, on July 01, 2020, Emcure Pharmaceuticals has introduced a generic version of sucroferric oxyhydroxide tablets, which are indicated for the control of increased serum phosphorus levels in patients with chronic kidney disease on dialysis. The sucroferric oxyhydroxide drug is sold under the brand name 'Dynulta' and is manufactured at the company's facility.
Hyperphosphatemia Drugs Market Key Segments:
By Type
- Calcium-based Phosphate Binders
- Magnesium-based Phosphate Binders
- Aluminum-based Phosphate Binders
- Iron-based Phosphate Binders
- Other Phosphate Binders
By Dosage Form
Key Global Hyperphosphatemia Drugs Industry Players
- Keryx Biopharmaceuticals
- Sun Pharmaceutical
- Ultragenyx
- Pfizer Inc
- Vifor Pharma
- Sanofi
- Takeda Pharmaceutical
- Fresenius Medical Care
- Emcure Pharma
- Ardelyx, Inc.
What Report Provides
- Full in-depth analysis of the parent Industry
- Important changes in market and its dynamics
- Segmentation details of the marketFormer, on-going, and projected market analysis in terms of volume and value
- Assessment of niche industry developments
- Market share analysis
- Key strategies of major players
- Emerging segments and regional growth potential
